Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ELVN stock hub

Enliven Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ELVNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.5B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ELVN

In the news

Latest news · ELVN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-26.6

P25 -105.6P50 -46.5P75 -3.1

ROIC-19.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ELVN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001672619
Company name	Enliven Therapeutics, Inc.
Country	United States
Country code	US
Cusip	29337E102
Employees	60
Employees Change	-2%
Employees Change Percent	-3.23
Enterprise value	$2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-03-12
Isin	US29337E1029
Last refreshed	2026-05-10
Market cap	$2.5B
Market cap category	Mid-Cap
Price	$40.75
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	ELVN
Website	https://www.enliventherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.98%
FCF yield	-2.64%
P/B ratio	5.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-98.8M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Profit Per Employee	$-1.6M
ROA	-18.86
Roa5y	-21.36
ROCE	-25.54
ROE	-26.64
Roe5y	-33.35
ROIC	-19.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	123.17%
Cagr3y	27.54%
EPS Growth Quarters	1
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$464.9M
Cash	$452.4M
Current Assets	$463.1M
Current Liabilities	$11.5M
Equity	$453.4M
Liabilities	$11.5M
Long Term Assets	$1.7M
Long Term Liabilities	$0
Net Cash	$452.4M
Net Cash By Market Cap	$18.23
Net Cash Growth	56.6%
Net Debt Equity	$-1
Tangible Book Value	$453.4M
Tangible Book Value Per Share	$7.45
WACC	6.75

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	40.32
Net Working Capital	$-751,000
Quick ratio	39.38
Working Capital	$451.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-21.96%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	123.04%
200-day SMA	25.36
3Y total return	107.49%
50-day SMA	37.58
50-day SMA vs 200-day SMA	50over200
All Time High	48.53
All Time High Change	-16.03%
All Time High Date	2026-04-17
All Time Low	9.8
All Time Low Change	315.82%
All Time Low Date	2023-12-12
ATR	2.29
Beta	0.45
Beta1y	0.59
Beta2y	0.96
Ch YTD	164.6
High	42.91
High52	48.53
High52 Date	2026-04-17
High52ch	-16.03%
Low	40.02
Low52	14.79
Low52 Date	2026-01-06
Low52ch	175.62%
Ma50ch	8.44%
Premarket Change Percent	-0.02
Premarket Price	$40.28
Premarket Volume	29,439
Price vs 200-day SMA	60.69%
RSI	48.22
RSI Monthly	69.67
RSI Weekly	64.37
Sharpe ratio	1.29x
Sortino ratio	2.68
Total Return	-21.96%
Tr YTD	164.6
Tr1m	-5.58%
Tr1w	-2.28%
Tr3m	38.51%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	1
Analyst Price Target Top	$56
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.42
Earnings Revenue Estimate	10,000x
Operating Income	$-115.8M
Price target	$47.8
Price Target Change	$17.3
Price Target Change Top	$37.42

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	35,472,334%
Float Percent	58.24%
Shares Insiders	3.29%
Shares Institutions	65.22%
Shares Out	60,904,946
Shares Qo Q	0.94%
Shares Yo Y	21.96%
Short Float	15.15%
Short Ratio	3.05
Short Shares	8.82

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-100.2M
Average Volume	713,874.8x
Bv Per Share	7.45
CAPEX	$-138,000
Ch1m	-5.58
Ch1w	-2.28
Ch1y	123
Ch3m	38.51
Ch3y	107.5
Ch6m	131.1
Change	1.14%
Change From Open	-1.95
Close	40.29
Days Gap	3.15
Depreciation Amortization	203,000
Dollar Volume	24,718,868.5
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-115.8M
EBITDA	$-115.6M
EPS	$-1.65
F Score	2
FCF	$-65.6M
FCF EV Yield	-3.23x
FCF Per Share	$-1.08
Financing CF	228,686,000
Fiscal Year End	December
Founded	2,016
Investing CF	-132,742,000
Ipr	154.7
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-03
Ma150	27.25
Ma150ch	49.55%
Ma20	43.48
Ma20ch	-6.28%
Net CF	30,479,000
Next Earnings Date	2026-08-12
Open	41.56
Optionable	Yes
Position In Range	25.26
Post Close	40.75
Postmarket Change Percent	-0.2
Postmarket Price	$40.67
Ppne	310,000
Pre Close	40.29
Price Date	2026-05-08
Ptbv Ratio	5.47
Relative Volume	0.85x
Share Based Comp	34,617,000
Tr6m	131.14%
Us State	Colorado
Volume	606,598

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ELVN pay a dividend?

Capital-return profile for this ticker.

Performance

ELVN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ELVN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+65.2%

Float: +58.2% of shares outstanding

Insider ownership

+3.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ELVN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

48.2

Neutral momentum band

Price vs 200-day MA

+60.7%

50/200-day relationship not available

Beta (5Y)

0.45

Less volatile than the market

Sharpe ratio

1.29

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ELVN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ELVN stock rating?

Enliven Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ELVN analysis?

The full report lives at /stocks/ELVN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ELVN?

The latest report frames ELVN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ELVN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.